Skeletal muscle regeneration after insulin-like growth factor I gene transfer by recombinant Sendai virus vector

A. Shiotani, M. Fukumura, M. Maeda, X. Hou, M. Inoue, T. Kanamori, S. Komaba, K. Washizawa, S. Fujikawa, T. Yamamoto, C. Kadono, K. Watabe, H. Fukuda, K. Saito, Y. Sakai, Y. Nagai, J. Kanzaki, M. Hasegawa

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

We scrutinized the applicability and efficacy of Sendai virus (SeV) vectors expressing either LacZ or human insulin-like growth factor-I (hIGF-I) in gene transfer into skeletal muscle. Seven days after the intramuscular injection of LacZ/SeV X-gal labeled myofibers were demonstrated in rat anterior tibialis muscle with/without bupivacaine treatment and the transgene expression persisted up to 1 month after injection. Recombinant hIGF-I was detected as a major protein species in culture supernatants of a neonatal rat myoblast cell line L6 and thus induced the cells to undergo myogenetic differentiation. The introduction of hIGF-I/SeV into the muscle showed a significant increase in regenerating and split myofibers which were indicative of hypertrophy, and also an increase in the total number of myofibers, in comparison to that seen in the LacZ/SeV-treated control muscle. These results demonstrate that SeV achieves high-level transgene expression in skeletal muscle, and that hIGF-I gene transfer using SeV vector may therefore have great potential in the treatment of neuromuscular disorders.

Original languageEnglish
Pages (from-to)1043-1050
Number of pages8
JournalGene Therapy
Volume8
Issue number14
DOIs
Publication statusPublished - 2001

Fingerprint

Sendai virus
Insulin-Like Growth Factor I
Regeneration
Skeletal Muscle
Genes
Transgenes
Muscles
Myoblasts
Bupivacaine
Intramuscular Injections
Hypertrophy
Cell Line
Injections
Therapeutics
Proteins

Keywords

  • IGF-I
  • Muscle regeneration
  • Sendai virus vector

ASJC Scopus subject areas

  • Genetics

Cite this

Shiotani, A., Fukumura, M., Maeda, M., Hou, X., Inoue, M., Kanamori, T., ... Hasegawa, M. (2001). Skeletal muscle regeneration after insulin-like growth factor I gene transfer by recombinant Sendai virus vector. Gene Therapy, 8(14), 1043-1050. https://doi.org/10.1038/sj.gt.3301486

Skeletal muscle regeneration after insulin-like growth factor I gene transfer by recombinant Sendai virus vector. / Shiotani, A.; Fukumura, M.; Maeda, M.; Hou, X.; Inoue, M.; Kanamori, T.; Komaba, S.; Washizawa, K.; Fujikawa, S.; Yamamoto, T.; Kadono, C.; Watabe, K.; Fukuda, H.; Saito, K.; Sakai, Y.; Nagai, Y.; Kanzaki, J.; Hasegawa, M.

In: Gene Therapy, Vol. 8, No. 14, 2001, p. 1043-1050.

Research output: Contribution to journalArticle

Shiotani, A, Fukumura, M, Maeda, M, Hou, X, Inoue, M, Kanamori, T, Komaba, S, Washizawa, K, Fujikawa, S, Yamamoto, T, Kadono, C, Watabe, K, Fukuda, H, Saito, K, Sakai, Y, Nagai, Y, Kanzaki, J & Hasegawa, M 2001, 'Skeletal muscle regeneration after insulin-like growth factor I gene transfer by recombinant Sendai virus vector', Gene Therapy, vol. 8, no. 14, pp. 1043-1050. https://doi.org/10.1038/sj.gt.3301486
Shiotani, A. ; Fukumura, M. ; Maeda, M. ; Hou, X. ; Inoue, M. ; Kanamori, T. ; Komaba, S. ; Washizawa, K. ; Fujikawa, S. ; Yamamoto, T. ; Kadono, C. ; Watabe, K. ; Fukuda, H. ; Saito, K. ; Sakai, Y. ; Nagai, Y. ; Kanzaki, J. ; Hasegawa, M. / Skeletal muscle regeneration after insulin-like growth factor I gene transfer by recombinant Sendai virus vector. In: Gene Therapy. 2001 ; Vol. 8, No. 14. pp. 1043-1050.
@article{7f8b14a005dd4725a347594ed773c8b8,
title = "Skeletal muscle regeneration after insulin-like growth factor I gene transfer by recombinant Sendai virus vector",
abstract = "We scrutinized the applicability and efficacy of Sendai virus (SeV) vectors expressing either LacZ or human insulin-like growth factor-I (hIGF-I) in gene transfer into skeletal muscle. Seven days after the intramuscular injection of LacZ/SeV X-gal labeled myofibers were demonstrated in rat anterior tibialis muscle with/without bupivacaine treatment and the transgene expression persisted up to 1 month after injection. Recombinant hIGF-I was detected as a major protein species in culture supernatants of a neonatal rat myoblast cell line L6 and thus induced the cells to undergo myogenetic differentiation. The introduction of hIGF-I/SeV into the muscle showed a significant increase in regenerating and split myofibers which were indicative of hypertrophy, and also an increase in the total number of myofibers, in comparison to that seen in the LacZ/SeV-treated control muscle. These results demonstrate that SeV achieves high-level transgene expression in skeletal muscle, and that hIGF-I gene transfer using SeV vector may therefore have great potential in the treatment of neuromuscular disorders.",
keywords = "IGF-I, Muscle regeneration, Sendai virus vector",
author = "A. Shiotani and M. Fukumura and M. Maeda and X. Hou and M. Inoue and T. Kanamori and S. Komaba and K. Washizawa and S. Fujikawa and T. Yamamoto and C. Kadono and K. Watabe and H. Fukuda and K. Saito and Y. Sakai and Y. Nagai and J. Kanzaki and M. Hasegawa",
year = "2001",
doi = "10.1038/sj.gt.3301486",
language = "English",
volume = "8",
pages = "1043--1050",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "14",

}

TY - JOUR

T1 - Skeletal muscle regeneration after insulin-like growth factor I gene transfer by recombinant Sendai virus vector

AU - Shiotani, A.

AU - Fukumura, M.

AU - Maeda, M.

AU - Hou, X.

AU - Inoue, M.

AU - Kanamori, T.

AU - Komaba, S.

AU - Washizawa, K.

AU - Fujikawa, S.

AU - Yamamoto, T.

AU - Kadono, C.

AU - Watabe, K.

AU - Fukuda, H.

AU - Saito, K.

AU - Sakai, Y.

AU - Nagai, Y.

AU - Kanzaki, J.

AU - Hasegawa, M.

PY - 2001

Y1 - 2001

N2 - We scrutinized the applicability and efficacy of Sendai virus (SeV) vectors expressing either LacZ or human insulin-like growth factor-I (hIGF-I) in gene transfer into skeletal muscle. Seven days after the intramuscular injection of LacZ/SeV X-gal labeled myofibers were demonstrated in rat anterior tibialis muscle with/without bupivacaine treatment and the transgene expression persisted up to 1 month after injection. Recombinant hIGF-I was detected as a major protein species in culture supernatants of a neonatal rat myoblast cell line L6 and thus induced the cells to undergo myogenetic differentiation. The introduction of hIGF-I/SeV into the muscle showed a significant increase in regenerating and split myofibers which were indicative of hypertrophy, and also an increase in the total number of myofibers, in comparison to that seen in the LacZ/SeV-treated control muscle. These results demonstrate that SeV achieves high-level transgene expression in skeletal muscle, and that hIGF-I gene transfer using SeV vector may therefore have great potential in the treatment of neuromuscular disorders.

AB - We scrutinized the applicability and efficacy of Sendai virus (SeV) vectors expressing either LacZ or human insulin-like growth factor-I (hIGF-I) in gene transfer into skeletal muscle. Seven days after the intramuscular injection of LacZ/SeV X-gal labeled myofibers were demonstrated in rat anterior tibialis muscle with/without bupivacaine treatment and the transgene expression persisted up to 1 month after injection. Recombinant hIGF-I was detected as a major protein species in culture supernatants of a neonatal rat myoblast cell line L6 and thus induced the cells to undergo myogenetic differentiation. The introduction of hIGF-I/SeV into the muscle showed a significant increase in regenerating and split myofibers which were indicative of hypertrophy, and also an increase in the total number of myofibers, in comparison to that seen in the LacZ/SeV-treated control muscle. These results demonstrate that SeV achieves high-level transgene expression in skeletal muscle, and that hIGF-I gene transfer using SeV vector may therefore have great potential in the treatment of neuromuscular disorders.

KW - IGF-I

KW - Muscle regeneration

KW - Sendai virus vector

UR - http://www.scopus.com/inward/record.url?scp=0034792827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034792827&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3301486

DO - 10.1038/sj.gt.3301486

M3 - Article

C2 - 11526451

AN - SCOPUS:0034792827

VL - 8

SP - 1043

EP - 1050

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 14

ER -